IMTX Immatics NV

In a report released on September 9, Jonathan Chang from SVB Securities reiterated a Buy rating on Immatics (IMTX - Research Report). The company's shares closed yesterday at $10.80.According to TipRanks, Chang is an analyst with an average return of -10.6% and a 27.98% success rate. Chang covers the Healthcare sector, focusing on stocks such as Immatics, Adaptimmune Therapeutics, and Bicycle Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immatics with a $28.00 average price target, representing a 159.26% upside. In a report released on September 9, Chardan Capital also reiterated a Buy rating on the stock with a $28.00 price target.
https://www.tipranks.com/news/blurbs/svb-securities-remains-a-buy-on-immatics-imtx?utm_source=advfn.com&utm_medium=referral